Caregivers of people living with dementia experience significant stress which can negatively affect their mental health. The goal of our study is to test a newly developed app that focuses on providing stress management strategies for caregivers of people living with dementia.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change from baseline in the Perceived Stress Scale-10 (PSS-10) total scores at 8-weeks
Timeframe: The PSS-10 will be administered at baseline (i.e., prior to starting the study) and immediately after the end of the intervention period (i.e., after a 8-week period)
Change from baseline in the Perceived Stress Scale-10 (PSS-10) total scores at a 4-week follow-up
Timeframe: The PSS-10 will be administered at baseline (i.e., prior to starting the study) and at a 4-week follow-up period
Change from after the 8-week period in the Perceived Stress Scale-10 (PSS-10) total scores at a 4-week follow-up
Timeframe: The PSS-10 will be administered immediately after the 8-week period and at a 4-week follow-up period
Change from baseline in the Burden Scale for Family Caregivers-Short Version (BSFC-S) total scores at 8-weeks
Timeframe: The BSFC-S will be administered at baseline (i.e., prior to starting the study) and immediately after the end of the intervention period (i.e., after a 8-week period)
Change from baseline in the BSFC-S total scores at a 4-week follow-up
Timeframe: The BSFC-S will be administered at baseline (i.e., prior to starting the study) and at a 4-week follow up
Change from after the 8-week period in the BSFC-S total scores at a 4-week follow-up
Timeframe: The BSFC-S will be administered immediately after the 8-week period and at a 4-week follow-up period
Change from baseline in the Patient Health Questionnaire-9 (PHQ-9) total scores at 8-weeks
Timeframe: The PHQ-9 will be administered at baseline (i.e., prior to starting the study) and immediately after the end of the intervention period (i.e., after a 8-week period)
Change from baseline in the PHQ-9 total scores at a 4-week follow-up
Timeframe: The PHQ-9 will be administered at baseline (i.e., prior to starting the study) and at a 4-week follow-up period
Change from after the 8-week period in the PHQ-9 total scores at a 4-week follow-up
Timeframe: The PHQ-9 will be administered immediately after the 8-week period and at a 4-week follow-up period
Change from baseline in the Generalized Anxiety Disorder-7 (GAD-7) total scores at 8-weeks
Timeframe: The GAD-7 will be administered at baseline (i.e., prior to starting the study) and immediately after the end of the intervention period (i.e., after a 8-week period)
Change from baseline in the GAD-7 total scores at a 4-week follow-up
Timeframe: The GAD-7 will be administered at baseline (i.e., prior to starting the study) and at a 4-week follow up period
Change from after the 8-week period in the GAD-7 total scores at a 4-week follow-up
Timeframe: The GAD-7 will be administered immediately after the 8-week period and at a 4-week follow-up period